Skip to main content
. Author manuscript; available in PMC: 2015 May 2.
Published in final edited form as: Eur Urol. 2011 Jan 18;60(1):21–28. doi: 10.1016/j.eururo.2011.01.017

Table 4.

Biopsies conducted and cancer detected per 1000 men with a clinical prostate biopsy based on the results from the Stockholm-1 study using a cross-validated predicted risk cut-off point of 20% or 25% as the threshold for biopsy for the nongenetic model, the genetic model, and the optimal genetic model

Model, % Performed Not performed % Cancer detected Cancer missed % Aggressive cancer detected Aggressive cancer missed %
Nongenetic 1000     0   0 365   0   0 60 0 0
20   949   51   5.10 352 13   3.60 59 1 1.70
25   871 129 12.90 338 27   7.40 56 4 6.70
Genetic
20   878 122 12.20 344 21   5.80 58 2 3.30
25   773 227 22.70 321 44 12 55 5 8.30
Optimal genetic
20   745 255 25.50 348 17   4.70 59* 1* 1.70
25   686 314 31.40 340 25   6.80 57* 3* 5